Healx

About Healx

Our mission is to accelerate treatments for rare diseases

Why rare diseases? Because we believe that every rare disease patient deserves a treatment.

There are over 7,000 rare diseases affecting 350 million people worldwide. Today, 95% of them are still without an approved treatment.

The traditional drug discovery model is focused on blockbuster drugs for large disease populations. As a result, rare disease patients are being let down. This is the reason why we developed Healnet, the world’s most comprehensive AI platform, which enables prediction of rare disease treatments at scale.

 

 

Leadership team

Dr Tim Guilliams

Dr Tim Guilliams

Co-Founder and Chief Executive Officer

Tim is a tech entrepreneur from the Cambridge Cluster (UK). He is passionate about using big data and artificial intelligence to accelerate treatments for rare diseases. He is the Co-Founder and Chief Executive of Healx Ltd, a tech company focused on treatment predictions for rare diseases. Healx was selected in the global 'Disrupt 100' list 2017, covered in the Harvard Business Review, finalist of Pitch@Palace and awarded 'Cambridge Startup of Year' 2016 and 'Cambridge Life Science Business of the Year' 2015.

Passionate about patient impact, Tim is also the Co-Founder and Trustee of the Cambridge Rare Disease Network (CRDN). Prior to Healx and CRDN, he obtained his PhD at the University of Cambridge in the field of Biophysics and Neuroscience, developing Nanobody technology for Parkinson's disease. Before moving to Cambridge UK, Tim obtained an MEng in Bio- and Chemical-Engineering from the University of Brussels.

Bio
Dr David Brown

Dr David Brown

Co-Founder and Chairman

Dr David Brown has 40 years experience in the pharmaceutical/biotechnology industry both in research and in senior executive roles. He served with four of the top 10 pharmaceutical companies: Zeneca, Pfizer, GlaxoWellcome and Hoffman La-Roche. Whilst at Pfizer he was named co-inventor on the patent for Viagra, and for 8 years he led the team that invented and developed Viagra through to proof of clinical efficacy in male impotence. The drug is also marketed for treatment of pulmonary hypertension under the trade name Revatio. He also had a pivotal role in the discovery of Relpax, a treatment for migraine. Together these drugs have achieved sales of over $40 billion. While at Roche in Switzerland, he was a Director of the company and, as Global Head of Drug Discovery, he had responsibility for productivity of over 2000 scientists at Roche’s five research sites in the USA, Europe and Asia.

David subsequently co-founded antibody company Crescendo Biologics and serves on the boards of Healx Ltd (Chair), ProFactor Pharma Ltd (Chair) and Babraham Institute Enterprise Ltd (Chair). He is a Trustee (Director) of Friends of Manjushree Vidyapith School and Orphanage (FMVSO), a charity he co-founded in 2005 to help destitute orphans in South Tibet.

Bio
Dr Neil Thompson

Dr Neil Thompson

Chief Scientific Officer

Neil has over 30 years’ experience in the biotech and pharmaceutical industries and a strong background working across a breadth of disease areas. His career has seen him involved in progressing more than 10 drugs into patients and he has led a number of drug discovery projects across a variety of therapeutic areas including cardiovascular, neurology, inflammation and oncology.

For 15 years, Neil was Senior Vice President of Biology at Astex Pharmaceuticals, helping to build the organisation and leading the biology and pre-clinical teams whose work has resulted in two new cancer drugs (Kisqali; ribociclib and Balversa; erdafitinib) reaching the market.

Since leaving Astex in 2017, Neil has been working as a consultant advising biotech companies worldwide on their drug discovery and development strategies. His earlier career included Director of the Immunology Platform at multinational pharmaceutical company GlaxoSmithKline (GSK), where his area of primary responsibility was specialist cellular and molecular immunology employed in the drug discovery process.

Neil is Deputy Chair of the UK MRC DPFS panel and Chair of the MRC CLD/ADI committee, has authored more than 40 publications and patents and sits on the advisory boards of several scientific institutions in the UK. He received his doctorate in Biochemistry from Kings College London.

Bio
Dr Ian Roberts

Dr Ian Roberts

Chief Technology Officer

As a senior investigator at the MRC Cancer Cell Unit, Cambridge, Ian led the development of molecular cytogenetic and genomics approaches for the discovery of disease genes in small round blue cell tumours and cervical carcinoma. During this time Ian developed algorithms for copy number imbalance analysis and integration with expression data using array-based techniques.

Following a move to industry, as Head of Informatics at Population Genetics Technologies Ltd, Ian led the development of next-generation DNA sequencing (NGS) variant discovery pipelines. Ian continued to develop NGS-based variant discovery workflows as Senior Bioinformatician at 14M Genomics before joining Healx in 2016.

Bio
Dr Kate Hilyard

Dr Kate Hilyard

Chief Operating Officer

Dr Kate Hilyard has over 25 years' experience in drug discovery working in the pharmaceutical, biotechnology and CRO industries. She has a track record of clear leadership building an integrated world-leading drug discovery organisation with a reputation for quality and delivery, using strong scientific, financial and commercial acumen to ensure a profitable and sustainable business generating growth in value to share-holders. Throughout her career she has been driven to make a difference to patient lives, from her early academic research in human biology at Oxford and Harvard Universities, to leading drug discovery teams and, ultimately, to leading organisations whose mission is to discover drugs through a sustainable business model.

Prior to joining Healx in July 2018, Kate was Corporate VP at Charles River Discovery, leading a team of over 400 scientists in three countries undertaking drug discovery for a global client base. Under her leadership the organization delivered on average 3-4 preclinical drug candidates per year for its partners.

Bio
Dr Michale Bouskila-Chubb

Dr Michale Bouskila-Chubb

Head of Business Development

Prior to joining Healx in 2017, Michale held various commercial positions in management consultancy, sales, technology transfer and pharmaceutical business development. Michale has a strong background in all aspects of IP exploitation from university technologies as well as commercial strategy. After a research career in physiology and human metabolism in both academia and industry, Michale completed an MBA specialising in life sciences from the Open University Business School. Michale also holds a Pharmacy doctorate and a Toxicology Master’s degree from Paris V University as well as a PhD from the University of Dundee.

Bio
Dr Michael Motskin

Dr Michael Motskin

Head of Digital Strategy

Colin Oakman

Colin Oakman

Finance Director

Dr Andrea Pierleoni

Dr Andrea Pierleoni

Head of AI

Download Healx Rare Treatment Award application form

`